false 0001022899 Protagenic Therapeutics, Inc.new 0001022899 2024-11-29 2024-11-29 0001022899 PTIX:ProtagenicTherapeuticsInc.CommonStockMember 2024-11-29 2024-11-29 0001022899 PTIX:ProtagenicTherapeuticsInc.CommonStockWarrantsMember 2024-11-29 2024-11-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported): November 29, 2024

 

PROTAGENIC THERAPEUTICS, INC.

 

(Exact name of Company as specified in its charter)

 

Delaware   001-12555   06-1390025

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

149 Fifth Avenue, Suite 500, New York, NY   10010
(Address of principal executive offices)   (Zip Code)

 

212-994-8200

 

(Company’s telephone number, including area code)

 

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
         
Protagenic Therapeutics, Inc. Common Stock   PTIX   Nasdaq
Protagenic Therapeutics, Inc. Common Stock Warrants   PTIXW   Nasdaq

 

 

 

 
 

 

Item 8.01. Other Events.

 

As previously disclosed, on May 22, 2024, the Nasdaq Listing Qualifications department (“Nasdaq”) informed Protagenic Therapeutics, Inc. (the “Company”) that it did not meet the minimum $2,500,000 stockholders’ equity requirement for continued listing as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Rule”).

 

Nasdaq initially provided the Company until July 8, 2024, to submit a plan to regain compliance. The Company submitted its compliance plan on time, and Nasdaq subsequently granted an extension to allow the Company to meet the requirements of the Rule.

 

While the Company made efforts to address the compliance requirements during the extension period, it was unable to meet the necessary stockholders’ equity threshold by November 18, 2024. Consequently, on November 19, 2024, Nasdaq issued a determination letter (the “Nasdaq Determination Letter”) notifying the Company of its non-compliance with the terms of the extension.

 

On November 27, 2024, the Company appealed the Nasdaq Determination Letter and requested a hearing (the “Hearing”) before the Nasdaq Hearings Panel (the “Panel”). On November 29, 2024, Nasdaq informed the Company that the delisting action has been stayed, pending a final written decision by the Panel. The Hearing is scheduled for January 30, 2025, and the deadline for submission of materials to the Panel is January 10, 2025. Nasdaq also provided detailed instructions regarding the Hearing process.

 

The Company is committed to working diligently to present a comprehensive plan to the Panel aimed at regaining compliance with the Rule. While the Company remains focused on achieving this objective, there can be no assurance that the Panel will grant the Company additional time to regain compliance or that the Company will meet all applicable requirements for continued listing on The Nasdaq Capital Market.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PROTAGENIC THERAPEUTICS, INC.
     
Date: December 3, 2024 By: /s/ Alexander K. Arrow
  Name: Alexander K. Arrow
  Title: Chief Financial Officer

 

 

v3.24.3
Cover
Nov. 29, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 29, 2024
Entity File Number 001-12555
Entity Registrant Name Protagenic Therapeutics, Inc.new
Entity Central Index Key 0001022899
Entity Tax Identification Number 06-1390025
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 149 Fifth Avenue
Entity Address, Address Line Two Suite 500
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10010
City Area Code 212
Local Phone Number 994-8200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Protagenic Therapeutics, Inc. Common Stock  
Title of 12(b) Security Protagenic Therapeutics, Inc. Common Stock
Trading Symbol PTIX
Security Exchange Name NASDAQ
Protagenic Therapeutics, Inc. Common Stock Warrants  
Title of 12(b) Security Protagenic Therapeutics, Inc. Common Stock Warrants
Trading Symbol PTIXW
Security Exchange Name NASDAQ
Protagenic Therapeutics (NASDAQ:PTIXW)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Protagenic Therapeutics Charts.
Protagenic Therapeutics (NASDAQ:PTIXW)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Protagenic Therapeutics Charts.